RAPT Therapeutics Downgraded to Neutral at HC Wainwright

RAPT Stock  USD 0.75  0.05  6.25%   
Slightly above 66% of RAPT Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding RAPT Therapeutics suggests that many traders are alarmed. RAPT Therapeutics' investing sentiment can be driven by a variety of factors including economic data, RAPT Therapeutics' earnings reports, geopolitical events, and overall market trends.
HC Wainwright cut shares of RAPT Therapeutics from a buy rating to a neutral rating in a research note published on Wednesday, MarketBeat Ratings reports. Other research analysts have also issued reports about the stock. JPMorgan Chase Co. boosted their price target on shares of RAPT Therapeutics from 32.00 to

Read at thelincolnianonline.com
news
  

RAPT Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards RAPT Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

RAPT Therapeutics Fundamental Analysis

We analyze RAPT Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

RAPT Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

RAPT Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with RAPT Therapeutics stock to make a market-neutral strategy. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics with similar companies.

Peers

RAPT Therapeutics Related Equities

IKNAIkena Oncology   4.63   
0%
34.0%
MOLNMolecular Partners   3.54   
0%
26.0%
STOKStoke Therapeutics   3.43   
0%
25.0%
CNTBConnect Biopharma   2.53   
0%
18.0%
RLAYRelay Therapeutics   1.69   
0%
12.0%
TYRATyra Biosciences   0.20   
0%
1.0%
PHVSPharvaris   0.29   
2.0%
0%
DSGNDesign Therapeutics   0.57   
4.0%
0%
PMVPPmv Pharmaceuticals   1.12   
8.0%
0%
XLOXilio Development   1.39   
10.0%
0%
ANTXAN2 Therapeutics   1.64   
12.0%
0%
PEPGPepGen   2.60   
19.0%
0%
ANEBAnebulo Pharmaceuticals   2.80   
20.0%
0%
ARVNArvinas   2.94   
21.0%
0%
BDTXBlack Diamond   2.96   
21.0%
0%
GLUEMonte Rosa   3.08   
22.0%
0%
PLRXPliant Therapeutics   3.42   
25.0%
0%
MLYSMineralys Therapeutics,   6.15   
45.0%
0%
HOWLWerewolf Therapeutics   8.05   
59.0%
0%
HCWBHCW Biologics   13.57   
100.0%
0%

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.